Absci stands out as a leading company in the biotech industry, leveraging deep learning AI and synthetic biology to expand the therapeutic potential of proteins, which allows for the creation of protein-based drugs that may not be possible with other technologies. Their Integrated Drug Creation™ Platform streamlines the process of drug discovery and manufacturing, offering a unique competitive advantage. Furthermore, their zero-shot AI approach designs antibodies from scratch, potentially reducing the time to get new drug leads into the clinic and unlocking treatments for traditionally "undruggable" diseases.